FDA Proposed Information Collection for Investigational New Drugs

Content

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection
of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish
notice in the
Federal Register
concerning each proposed collection of information, including each proposed extension of an existing collection of information,
and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection
associated with investigational new drugs and investigational new drug applications.

DATES:

Either electronic or written comments on the collection of information must be submitted by May 12, 2026.

ADDRESSES:

You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of May 12, 2026. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before
that date.

Electronic Submissions

Submit electronic comments in the following way:

• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring
that your comment does not include any confidential information that you or a third party may not wish to be posted, such
as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing
process. Please note that if you include your name, contact information, or other information that identifies you in the body
of your comments, that information will be posted on https://www.regulations.gov.

• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

• Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.” Instructions: All submissions received must include the Docket No. FDA-2026-N-1736 for “Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements.”

Received comments, those filed in a timely manner (see
ADDRESSES
), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

• Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available,
submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The
Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second
copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and
posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly
available, you can provide this information on the cover sheet and not in the body of your comments and you must identify
this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with
21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets,
see 80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts
and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT:

Anne Taylor, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North
Bethesda, MD 20852, 240-402-5683, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

Under the PRA (44 U.S.C. 3501-3521), Federal Agencies must obtain approval from the Office of Management and Budget (OMB)
for each collection of information they conduct or sponsor. “Collection of information” is defined in 44 U.S.C. 3502(3) and
5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide
information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide
a 60-day notice in the
Federal Register
concerning each proposed collection of information, including each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed
collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on these topics: (1) whether the proposed collection
of information is necessary for the proper performance of FDA's functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity
of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected;
and (4) ways to minimize the burden of the

  collection of information on respondents, including through the use of automated collection techniques, when appropriate,
  and other forms of information technology.

Investigational New Drug Application Requirements—21 CFR Part 312

OMB Control Number 0910-0014—Extension

This information collection supports implementation of provisions of section 505 of the Federal Food, Drug, and Cosmetic Act
(FD&C Act) (21 U.S.C. 355) and of the licensing provisions of the Public Health Service Act (42 U.S.C. 201 et seq.) that govern investigational new drugs and investigational new drug applications (INDs). Implementing regulations are found
in part 312 (21 CFR part 312), and provide for the issuance of guidance documents (see § 312.145 (21 CFR 312.145)) to assist
persons in complying with the applicable requirements. The information collection applies to all clinical investigations subject
to section 505 of the FD&C Act and include the following types of INDs:

• An Investigator IND is submitted by a physician who both initiates and investigates, and under whose immediate direction the investigational drug is administered or dispensed. A physician might submit a research IND to propose studying an unapproved drug or an approved product for a new indication or in a new patient population.
• Emergency Use IND allows FDA to authorize use of an experimental drug in an emergency situation that does not allow time for submission of an IND in accordance with § 312.23 or § 312.20 (21 CFR 312.23 or 312.20). It is also used for patients who do not meet the criteria of an existing study protocol or if an approved study protocol does not exist.
• Treatment IND is submitted for experimental drugs showing promise in clinical testing for serious or immediately life-threatening conditions while the final clinical work is conducted and FDA's review takes place. There are two IND categories: commercial and research (non-commercial).

General IND requirements include submitting an initial application as well as amendments to that application; submitting reports
on significant revisions of clinical investigation plans; submitting information to the clinical trials data bank (https://clinicaltrials.gov) established by the National Institutes of Health/National Library of Medicine, including expanded information on certain
clinical trials and information on the results of these clinical trials; and reporting information on a drug's safety or effectiveness.
In addition, sponsors are required to provide to FDA an annual summary of the previous year's clinical experience. The regulations
also include recordkeeping requirements regarding the disposition of drugs, records regarding individual case histories, and
certain other documentation verifying clinical investigators' fulfillment of responsibilities.

Form FDA 1571 entitled “Investigational New Drug Application (IND)” and Form FDA 1572 entitled “Statement of Investigator,”
were developed to assist respondents with the information collection and provide for uniform reporting of required data elements.
The information is required to be submitted electronically. Individuals who are interested in receiving printed forms may
send an email request to the FDA Forms Manager at formsmanager@OC.FDA.GOV. Fees may apply. Sponsors (including sponsor-investigators) interested in filing or updating a research IND may use a new web-based
interface developed for use by mobile device or desktop to help in completing Form FDA 1571. The web-based interface also
allows respondents to electronically submit completed Form FDA 1571 and associated files. Form FDA 1571 was recently updated
to include the new tracking information for real world evidence and real-world data (RWE/RWD). The new RWE/RWD fields will
capture submissions with RWE/RWD based on the requirements set forth in the PDUFA VII commitment letter and the resulting Advancing Real World Evidence Program, so that FDA can track and report on its performance related to these commitments. In addition, collection of this data will
support the consistent integration of real-world evidence data into the regulatory review and approval process for new drugs
and biologics. For more information regarding Forms FDA 1571 and 1572 visit https://www.fda.gov/news-events/expanded-access/how-complete-form-fda-1571-and-form-fda-1572.

Human drug, biological product, and device product submissions must be accompanied by Form FDA 3674, as discussed in the guidance
document entitled “Form FDA 3674—Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions”
(updated November 2017), available from our website at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/form-fda-3674-certifications-accompany-drug-biological-product-and-device-applicationssubmissions. The guidance document provides procedural instruction on completing and submitting required information to FDA. As communicated
in the instructions, the certification must accompany the application or submission and be included at the time of submission
to FDA.

Regulations in part 312, subpart B, specify content and format requirements for applications, amendments, annual reporting,
and withdrawals, including content and format requirements for protocol and information amendments. The regulations also explain
phases of an investigation and set forth principles of IND submissions. To date we have developed and issued the following
guidance documents to assist respondents:

• “ Establishment and Operation of Clinical Trial Data Monitoring Committees ” guidance (March 2006); and

• “ Special Protocol Assessment ” guidance (April 2018).

All Agency guidance documents are issued in accordance with our Good Guidance Practice regulations in 21 CFR 10.115, which
provide for public comment at any time. We maintain a searchable guidance database on our website at https://www.fda.gov/regulatory-information/search-fda-guidance-documents that utilizes topic specific search terms.

Regulations in part 312, subpart C, describe administrative actions pertaining to respondents' requests for and responses
to clinical holds, terminations, and inactive IND status determinations, as well as various types of meetings (for example,
End-of-Phase 2 and Pre-new drug application (NDA) meetings).

Regulations in part 312, subpart D, set forth sponsor and investigator responsibilities, including general responsibilities;
transfer of obligations to a contract research organization; recordkeeping and record retention controls; reporting responsibilities;
and responsibility for disposition of unused supply of investigational drug. The regulations also provide for investigator
controls including review of ongoing investigations; compliance with requirements regarding the protection of human subjects
and institutional review board assurance; and disqualification of clinical investigators.

Regulations in part 312, subpart E, sets forth requirements applicable to drugs intended to treat life-threatening and severely
debilitating illnesses. The

  regulations establish procedures to reflect that physicians and patients accept greater risk or side effects from products
  that treat life-threatening and severely debilitating illnesses than they would accept from products that treat less serious
  illnesses. The procedures also reflect the recognition that the benefits of the drug need to be evaluated in light of the
  severity of the disease being treated.

Regulations in part 312, subpart F, include provisions pertaining to import and export requirements; foreign clinical studies
not conducted under an IND; the disclosure of data and information in an IND; and the issuance of guidance documents. To date
we have developed and issued the following guidance documents to assist respondents:

• “ Oversight of Clinical Investigations ” guidance (August 2013);

• “ Pharmacogenomic Data Submissions ” guidance (March 2005);

• “ Adaptive Designs for Clinical Trials of Drugs and Biologics ” guidance (December 2019); and

• “ E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) ” guidance (March 2018).

All Agency guidance documents are issued in accordance with our Good Guidance Practice regulations in 21 CFR 10.115, which
provide for public comment at any time. We maintain a searchable guidance database on our website at https://www.fda.gov/regulatory-information/search-fda-guidance-documents that utilizes topic specific search terms.

Regulations in part 312, subpart G, provide for drugs for investigational use in laboratory research animals or in vitro tests.

Finally, 21 CFR 300.200 requires the submission of an annual report by sponsors and manufacturers who provide an “ eligible investigational drug ” under the Right to Try Act. The regulation also establishes content and format elements and requires that information be
submitted to FDA no later than March 31 of each year, including data for the preceding calendar year. Respondents use Form
FDA 5023 entitled “ Right to Try Reporting Requirement: Annual Summary,” currently available for download from our website at https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try-annual-reporting-summary. As required by the applicable statute, section 561B of the FD&C Act (21 U.S.C. 360bbb-0a), the information is submitted to
an FDA-designated point of contact, and in accordance with instructions to be posted at: https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try.

We estimate the burden of this collection of information as follows:

| 21 CFR section; activity | Number of
respondents | Number of
responses perrespondent | Total
annualresponses | Average
burden perresponse | Total hours |
| --- | --- | --- | --- | --- | --- |
| Subpart A—General Provisions: §§ 312.1 through 312.10 | | | | | |
| § 312.2(e); requests for FDA advice on the applicability of part 312 to a planned clinical investigation | 454 | 1.528 | 694 | 24 | 16,656 |
| § 312.8; requests to charge for an investigational drug | 14 | 1.64 | 23 | 48 | 1,104 |
| § 312.10; waiver requests | 5 | 1 | 5 | 24 | 120 |
| Subtotal Subpart A Center for Biologics Evaluation and Research (CBER) | | | 722 | | 17,880 |
| Subpart B—Investigational New Drug Application (IND): §§ 312.20 through 312.38 (Including Forms FDA 1571, 1572, and 3674) | | | | | |
| § 312.23(a) through (f); IND content and format | 2,075 | 3.382 | 7,018 | 300 | 2,105,400 |
| § 312.30(a) through (e); protocol amendments | 1,781 | 4.6692 | 8,316 | 284 | 2,361,744 |
| § 312.31(b); information amendments | 169 | 2.48 | 419 | 100 | 41,900 |
| § 312.32(c) and (d); IND safety reports | 224 | 10.59 | 2,372 | 32 | 75,904 |
| § 312.33(a) through (f); IND annual reports | 971 | 2.2739 | 2,208 | 360 | 794,880 |
| § 312.38(b) and (c); notifications of withdrawal of an IND | 712 | 3.057 | 2,177 | 28 | 60,956 |
| Subtotal Subpart B CBER | | | 22,510 | | 5,440,784 |
| Subpart C—Administrative Actions: §§ 312.40 through 312.48 | | | | | |
| § 312.42; clinical holds and requests for modification | 154 | 1.65 | 254 | 284 | 72,136 |
| § 312.44(c) and (d); sponsor responses to FDA when IND is terminated | 86 | 1.22 | 105 | 16 | 1,680 |
| § 312.45(a) and (b); sponsor requests for or responses to an inactive status determination of an IND by FDA | 48 | 1.48 | 71 | 12 | 852 |
| § 312.47; meetings, including “End-of-Phase 2” meetings and “Pre-NDA” meetings | 157 | 1.80 | 283 | 160 | 45,280 |
| Subtotal Subpart C CBER | | | 713 | | 119,948 |
| Subpart D—Responsibilities of Sponsors and Investigators: §§ 312.50 through 312.70 | | | | | |
| § 312.53(c); investigator reports submitted to the sponsor, including Form FDA 1572, curriculum vitae, clinical protocol,
and financial disclosure | 1,068 | 5.23 | 5,586 | 80 | 446,880 |
| § 312.54(a); sponsor submissions to FDA concerning investigations involving an exception from informed consent under § 50.24 | 4 | 4.25 | 17 | 48 | 816 |
| § 312.54(b); sponsor notifications to FDA and others concerning an institutional review board determination that it cannot
approve research because it does not meet the criteria in the exception from informed consent in § 50.24(a) | 1 | 1 | 1 | 48 | 48 |
| § 312.55(a); number of investigator brochures submitted by the sponsor to each investigator | 473 | 2.224 | 1,052 | 48 | 50,496 |
| § 312.55(b); number of sponsor reports to investigators on new observations, especially adverse reactions and safe use | 243 | 4.95 | 1,203 | 48 | 57,744 |
| § 312.56(b), (c), and (d); review of ongoing investigations and associated notifications; sponsor notifications | 915 | 2.948 | 2,698 | 80 | 215,840 |
| § 312.58; inspection of records and reports by FDA | 7 | 1 | 7 | 8 | 56 |
| § 312.64; number of investigator reports to the sponsor, including progress reports, safety reports, final reports, and financial
disclosure reports | 2,728 | 3.816 | 10,411 | 24 | 249,864 |
| § 312.70; disqualification of a clinical investigator by FDA | 5 | 1 | 5 | 40 | 200 |
| Subtotal Subpart D CBER | | | 20,980 | | 1,021,944 |
| Subpart F—Miscellaneous: §§ 312.110 through 312.145 | | | | | |
| § 312.110(b)(4) and (b)(5); number of written certifications and written statements submitted to FDA relating to the export
of an investigational drug | 18 | 1 | 18 | 75 | 1,350 |
| § 312.120(b); number of submissions to FDA of “supporting information” related to the use of foreign clinical studies not
conducted under an IND | 280 | 9.82 | 2,750 | 32 | 88,000 |
| § 312.120(c); number of waiver requests submitted to FDA related to the use of foreign clinical studies not conducted under
an IND | 7 | 2.29 | 16 | 24 | 384 |
| § 312.130; number of requests for disclosable information in an IND and for investigations involving an exception from informed
consent under § 50.24 | 350 | 1.342 | 470 | 8 | 3,760 |
| Subtotal Subpart F CBER | | | 3,254 | | 93,494 |
| Total | | | 48,179 | | 6,694,050 |
| 1 There are no capital costs or operating and maintenance costs associated with this collection of information. | | | | | |

| 21 CFR section; activity | Number of
recordkeepers | Number of
records perrecordkeeper | Total
annualrecords | Average
burden perrecordkeeping | Total hours |
| --- | --- | --- | --- | --- | --- |
| Subpart D—Responsibilities of Sponsors and Investigators: §§ 312.50 through 312.70 | | | | | |
| § 312.52(a); sponsor records for the transfer of obligations to a contract research organization | 94 | 2.26 | 212 | 2 | 424 |
| § 312.57; sponsor recordkeeping showing the receipt, shipment, or other disposition of the investigational drug, and any financial
interest | 335 | 2.70 | 904 | 100 | 90,400 |
| § 312.62(a); investigator recordkeeping of the disposition of drugs | 453 | 1 | 453 | 40 | 18,120 |
| § 312.62(b); investigator recordkeeping of case histories of individuals | 453 | 1 | 453 | 40 | 18,120 |
| Subtotal Subpart D CBER | | | 2,022 | | 127,064 |
| Subpart G—Drugs for Investigational Use in Laboratory Research Animals or In Vitro Tests | | | | | |
| § 312.160(a)(3); records pertaining to the shipment of drugs for investigational use in laboratory research animals or in
vitro tests | 111 | 1.40 | 155 | 0.5 (30 minutes) | 78 |
| § 312.160(c) shipper records of alternative disposition of unused drugs | 111 | 1.40 | 155 | 0.5 (30 minutes) | 78 |
| Subtotal Subpart G CBER | | | 310 | | 156 |
| Total | | | 2,332 | | 127,220 |
| 1 There are no capital costs or operating and maintenance costs associated with this collection of information. | | | | | |

| 21 CFR section; activity | Number of
respondents | Number of
responses perrespondent | Total
annualresponses | Average
burden perresponse | Total hours |
| --- | --- | --- | --- | --- | --- |
| Subpart A—General Provisions | | | | | |
| § 312.2(e); requests for FDA advice on the applicability of part 312 to a planned clinical investigation | 419 | 1 | 419 | 24 | 10,056 |
| § 312.8; requests to charge for an investigational drug | 25 | 1.28 | 32 | 48 | 1,536 |
| § 312.10; requests to waive a requirement in part 312 | 68 | 1.5 | 102 | 24 | 2,448 |
| Subtotal Subpart A Center for Drug Evaluation and Research (CDER) | | | 553 | | 14,040 |
| Subpart B—Investigational New Drug Application (IND) | | | | | |
| § 312.23(a) through (f); IND content and format (including Forms FDA 1571 and 3674) | 4,886 | 1.4662 | 7,164 | 300 | 2,149,200 |
| § 312.30(a) through (e); protocol amendments | 11,847 | 3.2367 | 38,346 | 284.25 | 10,899,850 |
| § 312.31(b); information amendments | 8,094 | 3.30899 | 26,783 | 100 | 2,678,300 |
| § 312.32(c) and (d); IND safety reports | 892 | 15.848 | 14,137 | 32 | 452,384 |
| § 312.33(a) through (f); IND annual reports | 3,777 | 2.9097 | 10,990 | 360 | 3,956,400 |
| § 312.38(b) and (c); notifications of withdrawal of an IND | 1,549 | 1.834 | 2,841 | 28 | 79,548 |
| § 312.145; Guidance Documents: | | | | | |
| Establishment and Operation of Clinical Trial Data Monitoring Committees (2006) | 37 | 32.027 | 1,185 | 1.515 | 1,795 |
| Special Protocol Assessment (2018)—Notification for Carcinogenicity Protocols | 106 | 1.78 | 189 | 8 | 1,510 |
| Requests for Special Protocol Assessment Reports | 113 | 1.03 | 116 | 15 | 1,740 |
| Subtotal Subpart B CDER | | | 101,751 | | 20,220,727 |
| Subpart C—Administrative Actions: §§ 312.40 through 312.48 | | | | | |
| § 312.42; clinical holds and requests for modifications | 181 | 1.28 | 232 | 284 | 65,888 |
| § 312.44(c) and (d); sponsor responses to FDA when IND is terminated | 1 | 1 | 1 | 16 | 16 |
| § 312.45(a) and (b); sponsor requests for or responses to an inactive status determination of an IND by FDA | 213 | 1.72 | 367 | 12 | 4,404 |
| § 312.47; meetings, including “End-of-Phase 2” meetings and “Pre-NDA” meetings | 174 | 2.885 | 502 | 160 | 80,320 |
| Subtotal Subpart C CDER | | | 1,102 | | 150,628 |
| Subpart D—Responsibilities of Sponsors and Investigators | | | | | |
| § 312.54(a); sponsor submissions to FDA concerning investigations involving an exception from informed consent under § 50.24 | 7 | 1.14 | 8 | 48 | 384 |
| § 312.54(b); sponsor notifications to FDA and others concerning an institutional review board determination that it cannot
approve research because it does not meet the criteria in the exception from informed consent in § 50.24(a) | 2 | 1 | 2 | 48 | 96 |
| § 312.56; review of ongoing investigations and associated notifications | 4,570 | 5.4689 | 24,993 | 80 | 1,999,440 |
| § 312.58; inspection of records and reports by FDA | 73 | 1 | 73 | 8 | 584 |
| § 312.70; disqualification of a clinical investigator by FDA. | 5 | 1 | 5 | 40 | 200 |
| Subtotal Subpart D CDER | | | 25,081 | | 2,000,704 |
| Subpart F—Miscellaneous: §§ 312.110 through 312.145 | | | | | |
| § 312.110(b)(4) and (b)(5); written certifications and written statements submitted to FDA relating to the export of an investigational
drug | 8 | 22.375 | 179 | 75 | 13,425 |
| § 312.120(b); submissions to FDA of “supporting information” related to the use of foreign clinical studies not conducted
under an IND | 1,964 | 7.352 | 14,440 | 32 | 462,080 |
| § 312.120(c); waiver requests submitted to FDA related to the use of foreign clinical studies not conducted under an IND | 68 | 1.5 | 102 | 24 | 2,448 |
| § 312.130; requests for disclosable information in an IND and for investigations involving an exception from informed consent
under § 50.24 | 3 | 1 | 3 | 8 | 24 |
| § 312.145; Guidance Documents: | | | | | |
| Oversight of Clinical Investigations (2013) | 88 | 1.5 | 132 | 4 | 528 |
| Pharmacogenomic Data Submissions (2005) | 1 | 1 | 1 | 50 | 50 |
| Adaptive Designs for Clinical Trials of Drugs and Biologics (2019) | 55 | 4.727 | 260 | 50 | 13,000 |
| E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) (2018) | 1,880 | 4.916 | 9,242 | 15.012 | 138,744 |
| Subtotal Subpart F CDER | | | 24,359 | | 630,299 |
| § 300.200; Right to try reporting requirements; submission of annual summary report using Form FDA 5023 | 10 | 1 | 10 | 2.5 | 25 |
| Total | | | 152,856 | | 23,016,423 |
| 1 There are no capital costs or operating and maintenance costs associated with this collection of information. | | | | | |

| 21 CFR section; activity | Number of
recordkeepers | Number of
records perrecordkeeper | Total
annualrecords | Average burden per
recordkeeping | Total hours |
| --- | --- | --- | --- | --- | --- |
| Subpart D—Responsibilities of Sponsors and Investigators | | | | | |
| § 312.52(a); transfer of obligations to a contract research organization | 466 | 3.107 | 1,448 | 300 | 434,400 |
| § 312.57; records showing the receipt, shipment, or other disposition of the investigational drug and any financial interests | 13,000 | 1 | 13,000 | 100 | 1,300,000 |
| § 312.62(a); records on disposition of drugs | 13,000 | 1 | 13,000 | 40 | 520,000 |
| § 312.62(b); records on case histories of individuals | 2,192 | 6.587 | 14,439 | 40 | 577,560 |
| Subtotal Subpart D CDER | | | 41,887 | | 2,831,960 |
| Subpart G—Drugs for Investigational Use in Laboratory Research Animals or In Vitro Tests | | | | | |
| § 312.160(a)(3); records pertaining to the shipment of drugs for investigational use in laboratory research animals or in
vitro tests | 547 | 1.43 | 782 | 0.50 (30 minutes) | 391 |
| § 312.160(c); shipper records of alternative disposition of unused drugs | 547 | 1.43 | 782 | 0.50 (30 minutes) | 391 |
| Subtotal | | | 1,564 | | 782 |
| Total | | | 43,451 | | 2,832,742 |
| 1 There are no capital costs or operating and maintenance costs associated with this collection of information. | | | | | |
Based on a review of the information collection since our last request for OMB approval, we have retained the annual burden
estimates for the majority of these activities. However, our estimated burden for the information

  collection reflects an overall increase of 22 hours. We attribute the increase to the correction of an inadvertent error in
  the reported hours for 21 CFR 300.200, which requires the submission of an annual report on Form FDA 5023 by sponsors and
  manufacturers who provide an “ *eligible investigational drug”* under the Right to Try Act.

Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs. [FR Doc. 2026-04938 Filed 3-12-26; 8:45 am] BILLING CODE 4164-01-P

Download File

Download